Triclofos

Summary

Triclofos (CHEMBL1201317) is an approved small molecule (ATC N05CM07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM07
• Clinical trials: 1
• Chemistry: 229.38 Da · C2H4Cl3O4P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201317
Name	Triclofos
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5563
ATC	N05CM07
Molecular formula	C2H4Cl3O4P
Molecular weight	229.38
InChIKey	YYQRGCZGSFRBAM-UHFFFAOYSA-N

SMILES: C(C(Cl)(Cl)Cl)OP(=O)(O)O

IUPAC name: 2,2,2-trichloroethyl dihydrogen phosphate

Also known as: Neguvon, Tri-beta-chloroethylphosphate, Triclofos, TRICLOFOS

Parent form; salt/anhydrous children: CHEMBL1200789

Patent coverage: 2,872 distinct patent families (7,375 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04270708	PHASE4	UNKNOWN	Intranasal Dexmedetomidine vs Oral Triclofos Sodium for EEG in Children With Autism

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).